6 research outputs found
Two dimensional bulge disk decomposition
We propose a two dimensional galaxy fitting algorithm to extract parameters
of the bulge, disk, and a central point source from broad band images of
galaxies. We use a set of realistic galaxy parameters to construct a large
number of model galaxy images which we then use as input to our galaxy fitting
program to test it. We find that our approach recovers all structural
parameters to a fair degree of accuracy. We elucidate our procedures by
extracting parameters for 3 real galaxies -- NGC 661, NGC 1381, and NGC 1427.Comment: 23 pages, LaTeX, AASTEX macros used, 7 Postscript figures, submitted
to Ap
Reaction-based Enumeration, Active Learning, and Free Energy Calculations to Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin Dependent Kinase 2 Inhibitors
We report a new computational technique, PathFinder, that uses retrosynthetic analysis followed by combinatorial synthesis to generate novel compounds in synthetically accessible chemical space. Coupling PathFinder with active learning and cloud-based free energy calculations allows for large-scale potency predictions of compounds on a timescale that impacts drug discovery. The process is further accelerated by using a combination of population-based statistics and active learning techniques. Using this approach,
we rapidly optimized R-groups and core hops for inhibitors of cyclin-dependent kinase 2. We explored greater than 300 thousand ideas and identified 35 ligands with diverse commercially available R-groups and a predicted IC<sub>50</sub> < 100 nM, and four unique cores with a predicted IC<sub>50</sub> < 100 nM. The rapid turnaround time, and scale of chemical exploration, suggests that this is a useful approach to accelerate the discovery of novel chemical matter in drug discovery campaigns.</jats:p
Reaction-based Enumeration, Active Learning, and Free Energy Calculations to Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin Dependent Kinase 2 Inhibitors
We report a new computational technique, PathFinder, that uses retrosynthetic analysis followed by combinatorial synthesis to generate novel compounds in synthetically accessible chemical space. Coupling PathFinder with active learning and cloud-based free energy calculations allows for large-scale potency predictions of compounds on a timescale that impacts drug discovery. The process is further accelerated by using a combination of population-based statistics and active learning techniques. Using this approach,
we rapidly optimized R-groups and core hops for inhibitors of cyclin-dependent kinase 2. We explored greater than 300 thousand ideas and identified 35 ligands with diverse commercially available R-groups and a predicted IC50 50 < 100 nM. The rapid turnaround time, and scale of chemical exploration, suggests that this is a useful approach to accelerate the discovery of novel chemical matter in drug discovery campaigns
Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors
Reaction-based Enumeration, Active Learning, and Free Energy Calculations to Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin Dependent Kinase 2 Inhibitors
We report a new computational technique, PathFinder, that uses retrosynthetic analysis followed by combinatorial synthesis to generate novel compounds in synthetically accessible chemical space. Coupling PathFinder with active learning and cloud-based free energy calculations allows for large-scale potency predictions of compounds on a timescale that impacts drug discovery. The process is further accelerated by using a combination of population-based statistics and active learning techniques. Using this approach,
we rapidly optimized R-groups and core hops for inhibitors of cyclin-dependent kinase 2. We explored greater than 300 thousand ideas and identified 35 ligands with diverse commercially available R-groups and a predicted IC50 50 < 100 nM. The rapid turnaround time, and scale of chemical exploration, suggests that this is a useful approach to accelerate the discovery of novel chemical matter in drug discovery campaigns
Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors
The hit-to-lead and lead optimization
processes usually involve
the design, synthesis, and profiling of thousands of analogs prior
to clinical candidate nomination. A hit finding campaign may begin
with a virtual screen that explores millions of compounds, if not
more. However, this scale of computational profiling is not frequently
performed in the hit-to-lead or lead optimization phases of drug discovery.
This is likely due to the lack of appropriate computational tools
to generate synthetically tractable lead-like compounds in silico,
and a lack of computational methods to accurately profile compounds
prospectively on a large scale. Recent advances in computational power
and methods provide the ability to profile much larger libraries of
ligands than previously possible. Herein, we report a new computational
technique, referred to as “PathFinder”, that uses retrosynthetic
analysis followed by combinatorial synthesis to generate novel compounds
in synthetically accessible chemical space. In this work, the integration
of PathFinder-driven compound generation, cloud-based FEP simulations,
and active learning are used to rapidly optimize R-groups, and generate
new cores for inhibitors of cyclin-dependent kinase 2 (CDK2). Using
this approach, we explored >300 000 ideas, performed >5000
FEP simulations, and identified >100 ligands with a predicted IC50 < 100 nM, including four unique cores. To our knowledge,
this is the largest set of FEP calculations disclosed in the literature
to date. The rapid turnaround time, and scale of chemical exploration,
suggests that this is a useful approach to accelerate the discovery
of novel chemical matter in drug discovery campaigns
